7265 Characterization of Treatment Intensified (Add-on To Metformin) Adults With Type 2 Diabetes Mellitus In Thailand: A cross sectional real-world study (CONVERGE)
Abstract
Abstract Disclosure: C. Sriphrapradang: Research Investigator; Self; Novo Nordisk. Speaker; Self; AstraZeneca, Bayer, Inc., Boehringer Ingelheim, Eli Lilly & Company, Novo Nordisk. R. Chinthammit: Employee; Self; 2.Novo Nordisk Pharma Thailand Ltd. G. Nayak: Employee; Self; Novo Nordisk Pharma Thailand Ltd. Background: Globally, 1 in 3 people with type 2 diabetes (T2D) have established cardiovascular disease (CVD), but only 2 in 10 receive antidiabetic agents (ADA) (members of glucagon-like peptide-1 receptor agonist [GLP-1RAs] and sodium-glucose co-transporter-2 inhibitors [SGLT-2is]) with proven CV benefits. Guidelines recommend a holistic approach to managing glycemic control and CVD risk. Understanding clinical characteristics and medication patterns in people with T2D in a local setting could help address the unmet needs in T2D management. Objective: The CONVERGE (Cardiovascular Outcomes and Value in the Real World with GLP-1RAs) study in three Asian countries (India, Pakistan, Thailand) involves two phases. Phase 1 characterizes eligible adults with T2D intensified on metformin (add-on to metformin) regarding demographics, clinical parameters, and medication patterns. Here we report findings from Thailand. Methods: Due to healthcare differences, a mosaic approach was used for the retrospective cross-sectional data collection based on medical record reviews. For Thailand, electronic medical record (EMR) data of eligible adults (≥18 years old) with T2D from December 12,…
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.